Description: Antibody-drug conjugates (ADCs) are complex biomolecules of antibodies linked to a cytotoxic drug. The antibody binds to a specific ligand on cancer cells, triggering uptake and release of a cytotoxic payload to destroy neoplastic tissue selectively. The goal is to deliver anticancer agents directly to tumors while minimizing systemic exposure.
This talk will discuss the bioanalytical challenges with ADCs and how they can be met using a microfluidic automated immunoassay format.
Learning Objectives:
Understand the different assay approaches needed to address the bioanalytical challenges associated with ADCs.
Highlight the advantages of a microfluidic, disc-based automated assay for antibody-drug conjugate (ADC) bioanalysis, including TK and PK assays.
Learn about case studies on developing TK (ADC), and PK (general) assays that meet project deadlines while producing higher quality data, conserving valuable reagents, and increasing throughput.
